Curis Lifesciences Limited · NSE:CURIS
Curis Lifesciences — Investor Presentation (March 2026)
23 slides from Curis Lifesciences's investor presentation, Mar 11, 2026
Slide 1: Cover letter to National Stock Exchange
11th March, 2026 To, The Listing Department National Stock Exchange of India Limited Exchange Plaza, 5" Floor, Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (E) Mumbai — 400051 Scrip Symbol : CURIS Subject: Investor Presentation Dear Sir/Madam, Pursuant to the Regulation 30 and other applicable
Slide 2: Investor Presentation
LIFE IS PRECIOUS INVESTOR PRESENTATION
Slide 3: Disclaimer
DISCLAIMER This presentation is created by Curis Lifesciences Ltd (the "Company") solely for informational purposes and does not constitute an offer, recommendation, or invitation to purchase or subscribe to any securities. It shall not be considered as the basis or relied upon in connection with an
Slide 4: Company Overview
COMPANY OVERVIEW Established in 2017, Curis Lifesciences Limited stands as a WHO-GMP certified pharmaceutical powerhouse in Ahmedabad, India, driving innovation through a robust portfolio of high-quality products for domestic and global markets. The company leverages a state-of-the-art facility to d
Slide 5: Management Team
MANAGEMENT TEAM Mr. Dharmesh Mr. Piyush Gordhanbhai Mr. Siddhant Jayantilbhai Mr. Jaimik Mansukhlal Dasharathbhai Patel Antala Pawasia Patel Chairman & Managing Whole-time Director Non-Executive Director Whole-time Director Director Pharmacy graduate with Pharmacy graduate from Founder of J D Buildc
Slide 6: Our Products
OUR PRODUCTS Discover our extensive portfolio of pharmaceutical products, Our offerings also include sterile and non-sterile, each produced thoughtfully formulated from solid and liquid forms to deliver adhering to regulatory standards, ensuring utmost care consistent adherence to every therapeutic
Slide 7: Business Model: Export Business
BUSINESS MODEL Export Business: Client based model Direct Export We have successfully built direct international partnerships, registering and supplying our products under our own license. Currently, we are directly engaged with two key markets: Yemen and Kenya. These direct exports enable us to bui
Slide 8: Domestic Market: Contract Manufacturing and Loan Licensing
Domestic Market: Contract Manufacturing We manufacture finished pharmaceutical formulations (tablets, capsules, liquids, ointments, ophthalmics) for leading companies, delivering consistent quality, compliance, and cost‑efficient production, while clients own the brand and manage sales and marketing
Slide 9: Clientele
CLIENTELE Fone uris SLIpca [RyUNSOLN HEALTHCARE FOR ALL anger ‘y Centurion Biogenics Pvt. Loa HEALTHCARE lol al al GL OUGII 4 = Arova== Costcon Healthcare LLP © CADILA —— PHARMACEUTICALS LIMITED The Care Continues press Pharmaceuticals Private Limited /VENUS International
Slide 10: Manufacturing Capabilities
MANUFACTURING CAPABILITIES Facility located at Sanand G.I.D.C-II, Ahmedabad, Gujarat – a well-established industrial hub with robust infrastructure and connectivity. It spans 2,827 sq. m. and has the following capacity (as on 31/03/2025). Product Production Capacity Capacity Utilization Tablets 1,3
Slide 11: In-House Capabilities: Tablets
IN-HOUSE CAPABILITIES 1. Tablets Granulation (Powder Preparation): Can process 100–500 kg of powder per batch, using wet granulation (250–500 kg) or dry granulation (100– 250 kg) methods. Compression (Tablet Formation): The tablet compression section is equipped with advanced high-speed presses, inc
Slide 12: Capsules, Liquid and Packing
2. Capsules The facility has a fully automatic capsule filling machine with online check weight, metal detection, sorting, and polishing, offering a filling capacity of 40,000 capsules per hour. 3. Liquid The facility is equipped with an automatic bottle filling and sealing machine with online visua
Slide 13: In-House Quality Testing Capabilities
IN-HOUSE QUALITY TESTING CAPABILITIES Microbiological Physical Testing Testing Verifies product attributes Ensures absence of (weight, hardness, harmful microorganisms disintegration, and validates product dissolution). safety. Confirms active Critical for ophthalmic pharmaceutical ingredients and o
Slide 14: Quality Standards & Licences
QUALITY STANDARDS & LICENCES We adhere to stringent regulatory standards and The company has been granted a follow Good Manufacturing Practices (GMP) to ensure the highest quality across all our products. manufacturing license by the relevant regulatory authority: Kenya & Ghana Financial obligations
Slide 15: Industry Overview
INDUSTRY OVERVIEW Pharmaceutical Contract Why India’s Growth Rate Exceeds Global? manufacturing (CM) Industry Export Focus India’s pharma CM market Strong shipments to US, Europe, grows 1.5x faster than global The global pharmaceutical contract emerging markets. due to structural edges. manufacturi
Slide 16: Why the Market Is Growing?
WHY THE MARKET IS GROWING? Outsourcing Non-Core Activities Large pharma firms outsource manufacturing to prioritize R&D and marketing, fueling 30-50% of Supply Chain Patent Cliff and Generics contract market expansion. Diversification Patent expirations trigger generic Geopolitical tensions drive f
Slide 17: African Pharmaceutical Market Analysis
AFRICAN PHARMACEUTICAL MARKET ANALYSIS Africa’s pharmaceutical market grows from ~USD 28 billion in 2024 to ~USD 44 billion by 2032 at a 6.1% CAGR, outpacing developed markets and offering high-margin opportunities for manufacturers like Curis—though entry requires 18-24 months for regulatory and di
Slide 18: Growth Prospects
GROWTH PROSPECTS Injectables – Strategic Growth Lever Scalable Regulatory Platform 1 3 Identified as a key capability to expand access to regulated Successful product registrations in Kenya create a international markets. regulatory template that can be replicated across other Planned entry over a 2
Slide 19: Operational Highlights
OPERATIONAL HIGHLIGHTS Congo Kenya Ghana Nigeria Product Portfolio Received two Registered 20 products Servicing 2–3 clients, Partnering with Strength: confirmed purchase via Centurion Pvt. Ltd. – ~20% of total Curis sales Eurosun 1,200+ products orders from Express key regulatory Onboarding new Pha
Slide 20: Profit and Loss Statement
PROFIT AND LOSS STATEMENT (Amt. in INR lakhs Except EPS) Particulars H1 FY26 H1 FY25 YoY% H2 FY25 HoH% Revenue 2790.89 1589.62 75.57% 3436.24 (18.78%) Other Income 0.12 0.12 0.00% 1.11 (89.19%) Total Income 2791.01 1589.74 75.56% 3437.35 (18.80%) Total Expense 2192.1 1208.33 81.42% 2743.03 (20.08%)
Slide 21: Balance Sheet
BALANCE SHEET (Amt. in INR lakhs) Particulars As on 30th Sept, 2025 As on 31st March, 2025 Equity Capital 593.44 593.44 Reserve & Surplus 1449.41 1058.32 Long-Term Borrowings 582.76 749.86 Other Non-Current Liabilities 119.59 118.92 Short-Term Borrowing 898.13 811.91 Other Current Liabilities 1295.9
Slide 22: Ratios
RATIOS 2790.89 598.91 7.1 421.09 75.57% 57.03% 381.41 91.09% 77.50% 1589.62 4 220.36 *H1 FY25 *H1 FY26 *H1 FY25 *H1 FY26 *H1 FY25 *H1 FY26 *H1 FY25 *H1 FY26 Revenue EBITDA PAT EPS (Amt. in INR lakhs) (Amt. in INR lakhs) (Amt. in INR lakhs) 40.00% 0.95 37.58% 0.72 20.61% 20.57% FY25 *H1 FY26 FY25 *H1
Slide 23: Thank You
THANK YOU REQUEST A MEETING IR@curisls.com Abhishek Bhutra | Himanshu Jain curisls.com +91 80006 85556 , +91 89051 81853 investorrelation@finportalin.com
Curis Lifesciences — Investor Presentation (March 2026) on 6ix